ADC - BiopharmaDirect

Antibody-Drug Conjugates

9 Nov 2020

Chemotherapy is currently one of the most widely used therapies in the field of tumor treatment. However, due to the huge side effects of chemotherapy, some patients are often unable to receive chemotherapy because of their low tolerance.

ADC Therapeutics Announces First Patient Dosed with Camidanlumab Tesirine (Cami) in Combination with Pembrolizumab in Ongoing Phase 1b Clinical Trial in Selected Solid Tumors

3 Nov 2020

ImmunoGen Announces FDA Breakthrough Therapy Designation for IMGN632 in Relapsed or Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm

5 Oct 2020

WALTHAM, Mass.--(BUSINESS WIRE)--Oct. 5, 2020-- ImmunoGen, Inc., (Nasdaq: IMGN) a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for IMGN632 for the treatment of patients with relapsed or refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN).